Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited
Your view on NURPF
Overview
What the company does, where it operates, and who runs it.
About Neuren Pharmaceuticals Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jonathan Charles Pilcher
- Headquarters
- 697 Burke Road, Camberwell, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jonathan Charles Pilcher
- Headquarters
- 697 Burke Road, Camberwell, VIC, AU
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome.
The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Neuren Pharmaceuticals Limited, and the rating behind it. NURPF last traded at $8.53, 127.9× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Neuren Pharmaceuticals Limited. Starting points for Neuren Pharmaceuticals Limited: P/E 127.9, EPS $0.16, beta 1.74 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Neuren Pharmaceuticals Limited. Neuren Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Neuren Pharmaceuticals Limited. Trailing twelve-month EPS for Neuren Pharmaceuticals Limited stands at $0.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Neuren Pharmaceuticals Limited. Neuren Pharmaceuticals Limited has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Neuren Pharmaceuticals Limited valued side by side against its closest peers. Neuren Pharmaceuticals Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Neuren Pharmaceuticals Limited, and how their positions are changing. At a $1.07B market value, institutional positions materially move Neuren Pharmaceuticals Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Neuren Pharmaceuticals Limited executives and directors. Shares of Neuren Pharmaceuticals Limited have traded between $6.60 and $14.80 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Neuren Pharmaceuticals Limited. Neuren Pharmaceuticals Limited is a $1.07B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Neuren Pharmaceuticals Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Neuren Pharmaceuticals Limited. Coverage tracks Neuren Pharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.